Feb Ben in Stage 4
Fenbendazole and cancerhttps://karger.com/cro/article-pdf/18/1/856/4381509/000546362.pdf
Fenbendazole, inexpensive, widely accessible antiparasitic drug used in veterinary medicine
Patent expired in the early 1990s, making FBZ available as a generic drug
Case 1
An 83-year-old female
October 2021
Stage 4 breast cancer
Initially diagnosed in 2009
Treated 2009, bilateral mastectomy
Recurrence was diagnosed in 2021.
Liver biopsy, confirmed metastatic breast
Ascitic fluid confirmed metastatic breast carcinoma.
Magnetic resonance imaging of the spine, October 2021 metastatic breast cancer, T10, T12, L1, L2, L3, L4, L5, S1, S2, and the iliac bones.
A PET/CT scan on December 29, 2021, showed six hypermetabolic lung lesions
Largest was 2.8 × 1.5 cm
Hypermetabolic liver lesions, 2.9 × 1.7 cm
Hypermetabolic bone lesions, notably a 5.0 × 2.9 cm lytic lesion in L4, extending into the spinal canal, etc
The patient declined further conventional chemotherapy or radiation therapy and was placed under hospice care.
November 22, 2021
Self-administering FBZ daily at a dose of 222 mg.
In December 2021, she received fulvestrant injection, (an estrogen receptor blocker) intended to inhibit cancer growth
January 2022
Targeted radiation for two painful spinal metastases.
These tumors disappeared rapidly, relieving her pain within a few days.
Continued taking 222 mg/day of FBZ for 8 months.
During this time, her liver enzymes normalized
CA 27.29 tumor marker dropped from 316 (November 2021) to 36.6 (July 2022)
April 20, 2022,
PET scan confirmed the absence of any abnormal metabolic activity indicative of cancer.
June 2022
Patient was confirmed to have no evidence of active disease.
All treatments were discontinued, and she was considered to be in complete remission.
Follow-up monitoring was scheduled every 3–6 months.
Throughout her FBZ treatment, she continued her regular supplementation of vitamin D (5,000 IU) and a multivitamin.
Subsequent PET scans showed no abnormal metabolic activity.
The FBZ treatment period revealed no adverse effects at this dosage.
The patient remains recurrence-free and continues to take FBZ daily nearly 3 years after being declared to be in remission.
Joe Tipp’s Protocol
https://www.fenbendazole.org/fenbendazole-information/fenbendazole-dosage-guide/
Case 2, Prostate cancer, 75 year old man
Bone scans and CT scans, metastases in the spine, pelvic bones, and right humeral head
Conventional treatments
Complementary treatments
The use of FBZ coincided with continued regression of metastatic lesions and sustained undetectable PSA levels
After 26 months of sustained regression and no new progression, the patient remains in near-complete response and continues FBZ with conventional therapy
Case 3, 63-year-old man
Hip growth, melanoma.
PET-CT showed multiple hypermetabolic foci – peritoneal and retroperitoneal nodules, focal uptake in the stomach and small bowel, lesions in the right gluteus medius, quadratus femoris, and L5 vertebra.
Conventional and complementary treatments
The patient remains melanoma recurrence-free over 11 months after being declared to be in remission.
Case Presentations
All three patients, no reported adverse effects
Conclusion
FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology.
Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use. Receive SMS online on sms24.me
TubeReader video aggregator is a website that collects and organizes online videos from the YouTube source. Video aggregation is done for different purposes, and TubeReader take different approaches to achieve their purpose.
Our try to collect videos of high quality or interest for visitors to view; the collection may be made by editors or may be based on community votes.
Another method is to base the collection on those videos most viewed, either at the aggregator site or at various popular video hosting sites.
TubeReader site exists to allow users to collect their own sets of videos, for personal use as well as for browsing and viewing by others; TubeReader can develop online communities around video sharing.
Our site allow users to create a personalized video playlist, for personal use as well as for browsing and viewing by others.
@YouTubeReaderBot allows you to subscribe to Youtube channels.
By using @YouTubeReaderBot Bot you agree with YouTube Terms of Service.
Use the @YouTubeReaderBot telegram bot to be the first to be notified when new videos are released on your favorite channels.
Look for new videos or channels and share them with your friends.
You can start using our bot from this video, subscribe now to Feb Ben in Stage 4
What is YouTube?
YouTube is a free video sharing website that makes it easy to watch online videos. You can even create and upload your own videos to share with others. Originally created in 2005, YouTube is now one of the most popular sites on the Web, with visitors watching around 6 billion hours of video every month.
